Marion E. Morrison

A Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial of Oral Brincidofovir for Cytomegalovirus Prophylaxis in Allogeneic Hematopoietic Cell Transplantation

Francisco M. Marty, Drew J. Winston, Roy F. Chemaly et al. · Biology of Blood and Marrow Transplantation · 2018 · 210 citations · Full text

Brincidofovir for Asymptomatic Adenovirus Viremia in Pediatric and Adult Allogeneic Hematopoietic Cell Transplant Recipients: A Randomized Placebo-Controlled Phase II Trial

Michael Grimley, Roy F. Chemaly, Janet A. Englund et al. · Biology of Blood and Marrow Transplantation · 2017 · 156 citations · Full text

Short-term clinical safety profile of brincidofovir: A favorable benefit–risk proposition in the treatment of smallpox

Greg Chittick, Marion E. Morrison, Thomas M. Brundage et al. · Antiviral Research · 2017 · 126 citations

Antiviral Therapy, Virology, Favorable Benefit–risk Proposition +4

Brincidofovir Is Not a Substrate for the Human Organic Anion Transporter 1: A Mechanistic Explanation for the Lack of Nephrotoxicity Observed in Clinical Studies

Timothy K. Tippin, Marion E. Morrison, Thomas M. Brundage et al. · Therapeutic Drug Monitoring · 2016 · 70 citations · Full text

Brincidofovir for Prevention of Cytomegalovirus (CMV) after Allogeneic Hematopoietic Cell Transplantation (HCT) in CMV-Seropositive Patients: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Phase 3 Trial

Francisco M. Marty, Drew J. Winston, Roy F. Chemaly et al. · Biology of Blood and Marrow Transplantation · 2016 · 38 citations · Full text

Transplantation, Cmv Replication, Cmv Disease +13